CL2020002522A1 - Agentes de unión a c3 y métodos para su uso - Google Patents
Agentes de unión a c3 y métodos para su usoInfo
- Publication number
- CL2020002522A1 CL2020002522A1 CL2020002522A CL2020002522A CL2020002522A1 CL 2020002522 A1 CL2020002522 A1 CL 2020002522A1 CL 2020002522 A CL2020002522 A CL 2020002522A CL 2020002522 A CL2020002522 A CL 2020002522A CL 2020002522 A1 CL2020002522 A1 CL 2020002522A1
- Authority
- CL
- Chile
- Prior art keywords
- binding agents
- methods
- encode
- antibodies
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862652253P | 2018-04-03 | 2018-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002522A1 true CL2020002522A1 (es) | 2021-02-26 |
Family
ID=66630340
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002522A CL2020002522A1 (es) | 2018-04-03 | 2020-09-29 | Agentes de unión a c3 y métodos para su uso |
| CL2021002039A CL2021002039A1 (es) | 2018-04-03 | 2021-08-02 | Agentes de unión a c3 y métodos para su uso (divisional de la solicitud n° 202002522) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021002039A CL2021002039A1 (es) | 2018-04-03 | 2021-08-02 | Agentes de unión a c3 y métodos para su uso (divisional de la solicitud n° 202002522) |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11136381B2 (enExample) |
| EP (1) | EP3790897A1 (enExample) |
| JP (2) | JP7477457B2 (enExample) |
| KR (1) | KR20200138290A (enExample) |
| CN (1) | CN112105638A (enExample) |
| AR (1) | AR117565A1 (enExample) |
| AU (1) | AU2019248557A1 (enExample) |
| BR (1) | BR112020019907A2 (enExample) |
| CA (1) | CA3093356A1 (enExample) |
| CL (2) | CL2020002522A1 (enExample) |
| CO (1) | CO2020013468A2 (enExample) |
| IL (1) | IL277404A (enExample) |
| MX (1) | MX2020010323A (enExample) |
| PE (1) | PE20212132A1 (enExample) |
| PH (1) | PH12020500664A1 (enExample) |
| SG (1) | SG11202008897SA (enExample) |
| TW (1) | TWI833742B (enExample) |
| WO (1) | WO2019195136A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11136381B2 (en) | 2018-04-03 | 2021-10-05 | Ngm Biopharmaceuticals, Inc. | Anti-C3 antibodies |
| WO2021226442A2 (en) | 2020-05-08 | 2021-11-11 | Ngm Biopharmaceuticals, Inc. | Therapeutic uses of c3-binding agents |
| EP4213808A4 (en) * | 2020-09-21 | 2024-05-22 | Apellis Pharmaceuticals, Inc. | Methods of treating eye disorders |
| US20220259296A1 (en) * | 2021-02-12 | 2022-08-18 | Boehringer Ingelheim International Gmbh | Complement c3 antigen binding proteins |
| PE20250390A1 (es) * | 2021-12-22 | 2025-02-11 | Boehringer Ingelheim Int | Anticuerpos anti-c3 y fragmentos de union al antigeno de estos y sus usos para tratar enfermedades oftalmicas u oculares |
| WO2024086555A1 (en) * | 2022-10-17 | 2024-04-25 | Ngm Biopharmaceuticals, Inc. | Uses of anti-c3 antibodies |
| CN117447601B (zh) * | 2023-12-22 | 2024-03-08 | 北京索莱宝科技有限公司 | 猪IgM的抗体、抗体组合物及其应用 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002524533A (ja) * | 1998-09-10 | 2002-08-06 | ザ ユニヴァーシティー オブ ヴァージニア パテント ファウンデーション | 癌細胞に診断薬及び治療薬をデリバリーするためのＣ３ｂ（ｉ）に対する抗体 |
| AU2003271681A1 (en) | 2002-10-04 | 2004-04-23 | Sanquin Blood Supply Foundation Amsterdam | Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation |
| US7816497B2 (en) | 2002-10-30 | 2010-10-19 | University Of Kentucky | Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration |
| EP1558645B1 (en) * | 2002-11-08 | 2011-07-27 | Ablynx N.V. | Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation |
| US20090004183A1 (en) | 2004-07-23 | 2009-01-01 | Taylor Ronald P | Compositions and Methods for Regulating the Alternative Pathway of Complement |
| CA2593846A1 (en) | 2005-01-14 | 2006-08-10 | The Regents Of The University Of California | Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| DK2500030T4 (en) | 2005-11-04 | 2018-10-29 | Genentech Inc | Use of complement pathway inhibitors for the treatment of eye diseases |
| EP2148691B1 (en) | 2007-02-05 | 2015-05-20 | Apellis Pharmaceuticals, Inc. | Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system |
| US9745367B2 (en) | 2007-03-23 | 2017-08-29 | Novelmed Theraputics, Inc. | Alternative pathway specific antibodies for treating arthritis |
| US8192742B2 (en) | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
| AU2008262048B2 (en) | 2007-06-07 | 2013-09-26 | Genentech, Inc. | C3b antibodies and methods for the prevention and treatment of complement- associated disorders |
| US20100291106A1 (en) * | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
| AU2010250452B2 (en) | 2009-05-20 | 2014-06-05 | Toray Industries, Inc. | Cell membrane-permeable peptides |
| US9291622B2 (en) | 2009-05-21 | 2016-03-22 | Apellis Pharmaceuticals, Inc. | Complement assays and uses thereof |
| US20130177567A1 (en) | 2010-05-18 | 2013-07-11 | Sydansk Universitet | Novel c3c epitope, antibodies binding thereto, and use thereof |
| BR112012033119A2 (pt) | 2010-06-22 | 2016-10-25 | Univ Colorado Regents | anticorpos para o fragamento c3d do componente do complemento 3. |
| AU2013243574B2 (en) * | 2012-04-03 | 2017-12-07 | Novelmed Therapeutics, Inc | Humanized and chimeric anti-factor C3 antibodies and uses thereof |
| EP3086809A4 (en) | 2013-12-24 | 2017-11-29 | NovelMed Therapeutics, Inc. | Compositions and methods of treating ocular diseases |
| MX2016014504A (es) | 2014-05-05 | 2017-05-23 | Regeneron Pharma | Animales c5 y c3 humanizados. |
| US10815276B2 (en) | 2014-05-21 | 2020-10-27 | Entrada Therapeutics, Inc. | Cell penetrating peptides and methods of making and using thereof |
| WO2016094679A1 (en) * | 2014-12-10 | 2016-06-16 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| US20180346531A1 (en) | 2015-09-15 | 2018-12-06 | Regents Of The University Of California | Compositions and methods for delivering biotherapeutics |
| KR20180090785A (ko) | 2015-10-07 | 2018-08-13 | 아펠리스 파마슈티컬스 인코포레이티드 | 투여 요법 |
| RU2630647C1 (ru) * | 2016-05-27 | 2017-09-11 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА |
| US10905770B2 (en) | 2017-07-17 | 2021-02-02 | Macregen, Inc. | Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases |
| US11136381B2 (en) | 2018-04-03 | 2021-10-05 | Ngm Biopharmaceuticals, Inc. | Anti-C3 antibodies |
-
2019
- 2019-04-01 US US16/371,684 patent/US11136381B2/en active Active
- 2019-04-01 MX MX2020010323A patent/MX2020010323A/es unknown
- 2019-04-01 CA CA3093356A patent/CA3093356A1/en active Pending
- 2019-04-01 AR ARP190100853A patent/AR117565A1/es unknown
- 2019-04-01 TW TW108111549A patent/TWI833742B/zh active
- 2019-04-01 SG SG11202008897SA patent/SG11202008897SA/en unknown
- 2019-04-01 PE PE2020001505A patent/PE20212132A1/es unknown
- 2019-04-01 AU AU2019248557A patent/AU2019248557A1/en not_active Abandoned
- 2019-04-01 JP JP2020554097A patent/JP7477457B2/ja active Active
- 2019-04-01 KR KR1020207030405A patent/KR20200138290A/ko active Pending
- 2019-04-01 EP EP19725880.9A patent/EP3790897A1/en not_active Withdrawn
- 2019-04-01 BR BR112020019907-9A patent/BR112020019907A2/pt not_active Application Discontinuation
- 2019-04-01 WO PCT/US2019/025123 patent/WO2019195136A1/en not_active Ceased
- 2019-04-01 CN CN201980027315.6A patent/CN112105638A/zh active Pending
-
2020
- 2020-09-16 IL IL277404A patent/IL277404A/en unknown
- 2020-09-29 CL CL2020002522A patent/CL2020002522A1/es unknown
- 2020-10-01 PH PH12020500664A patent/PH12020500664A1/en unknown
- 2020-10-26 CO CONC2020/0013468A patent/CO2020013468A2/es unknown
-
2021
- 2021-08-02 CL CL2021002039A patent/CL2021002039A1/es unknown
- 2021-08-19 US US17/406,991 patent/US11767359B2/en active Active
-
2023
- 2023-08-10 US US18/447,741 patent/US20230382985A1/en not_active Abandoned
-
2024
- 2024-02-13 JP JP2024019502A patent/JP2024056851A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11767359B2 (en) | 2023-09-26 |
| SG11202008897SA (en) | 2020-10-29 |
| JP2021520195A (ja) | 2021-08-19 |
| RU2020135712A (ru) | 2022-05-04 |
| US11136381B2 (en) | 2021-10-05 |
| AR117565A1 (es) | 2021-08-18 |
| JP2024056851A (ja) | 2024-04-23 |
| US20230382985A1 (en) | 2023-11-30 |
| CL2021002039A1 (es) | 2022-04-01 |
| MX2020010323A (es) | 2021-01-08 |
| US20190322730A1 (en) | 2019-10-24 |
| PH12020500664A1 (en) | 2021-06-07 |
| WO2019195136A1 (en) | 2019-10-10 |
| CO2020013468A2 (es) | 2020-11-10 |
| KR20200138290A (ko) | 2020-12-09 |
| IL277404A (en) | 2020-11-30 |
| TWI833742B (zh) | 2024-03-01 |
| US20220119508A1 (en) | 2022-04-21 |
| BR112020019907A2 (pt) | 2021-01-05 |
| AU2019248557A1 (en) | 2020-09-24 |
| TW202003559A (zh) | 2020-01-16 |
| EP3790897A1 (en) | 2021-03-17 |
| CN112105638A (zh) | 2020-12-18 |
| PE20212132A1 (es) | 2021-11-05 |
| JP7477457B2 (ja) | 2024-05-01 |
| CA3093356A1 (en) | 2019-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020013468A2 (es) | Agentes de unión a c3 y métodos para su uso | |
| CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
| CL2020003031A1 (es) | Agentes aglutinantes del psma y usos de estos. | |
| MX2025009222A (es) | Agentes de union a clec9a y su uso | |
| CO2022008272A2 (es) | Agentes de unión a ilt3 y métodos de uso de los mismos | |
| ECSP21026339A (es) | Anticuerpos antihlag, composiciones que comprenden anticuerpos antihlag y métodos de uso de anticuerpos antihlag | |
| CO2022015208A2 (es) | Agentes de unión a ilt y métodos para su uso | |
| CO2021013279A2 (es) | Anticuerpos de cadena pesada que se unen al psma | |
| MX2021002970A (es) | Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor. | |
| CL2020002841A1 (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| CL2021003343A1 (es) | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3. | |
| MX2020004561A (es) | Anticuerpos biespecificos que se unen a alk-1 y bmpr-2. | |
| MX2019009468A (es) | Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer. | |
| MX2019009848A (es) | Proteínas que se unen a her2, nkg2d y cd16. | |
| MX2017014955A (es) | Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos. | |
| CO2018009995A2 (es) | Proteínas de unión y métodos de uso de las mismas | |
| CO2018011364A2 (es) | Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos | |
| MX2022015258A (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos. | |
| CO2017001558A2 (es) | Anticuerpos anti-lag3 y fragmentos de unión a antígeno | |
| MX2017006626A (es) | Cadenas ligeras comunes y metodos de uso. | |
| MX2018000621A (es) | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos. | |
| MX2018004515A (es) | Agentes de anticuerpo especificos para cd19 humano y usos de los mismos. | |
| CL2022003684A1 (es) | Agentes de unión a lair-1 y métodos para su uso | |
| MX2023010076A (es) | Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas. | |
| EA201892225A1 (ru) | АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ |